Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 225,098,311 papers from all fields of science
Search
Sign In
Create Free Account
H 74
Known as:
H-74
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
1 relation
Broader (1)
Acetonitriles
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2011
2011
H-74 ZEBに向けた再生可能エネルギー利用システムの計画手法に関する研究開発 : (その2) 要素機器のモデル構築及び精度検証
小野 永吉
,
荒井 良延
,
三浦 克弘
,
三原 邦彰
,
日野 俊之
,
藤井 義久
2011
Corpus ID: 175404581
1994
1994
[Acquired resistance and cross-resistance of gemcitabine to cisplatin or vindesine in human lung cancer xenografted in nude mice].
F. Fujita
,
M. Fujita
,
Y. Sakamoto
Gan to kagaku ryoho. Cancer & chemotherapy
1994
Corpus ID: 3141074
1994
1994
[Antitumor activity of combination treatment combining gemcitabine with cisplatin or vindesine against human lung cancer xenografted in nude mice].
F. Fujita
,
M. Fujita
,
Y. Sakamoto
Gan to kagaku ryoho. Cancer & chemotherapy
1994
Corpus ID: 21574200
1993
1993
[Antitumor activity of BOF-A2, a new 5-fluorouracil derivative, against human cancers xenografted in nude mice by intermittent administration].
F. Fujita
,
M. Fujita
,
H. Inaba
,
T. Taguchi
Gan to kagaku ryoho. Cancer & chemotherapy
1993
Corpus ID: 37768475
Antitumor effects of BOF-A2 given intermittently was evaluated with human gastric (H-111, H-83), colorectal (H-110, H-143) and…
Expand
1993
1993
[Antitumor activity of combination treatment of BOF-A2 with CDDP against human lung cancers xenografted in nude mice].
F. Fujita
,
M. Fujita
,
Y. Sakamoto
,
T. Taguchi
Gan to kagaku ryoho. Cancer & chemotherapy
1993
Corpus ID: 20826251
CDDP, commonly used in cancer chemotherapy, behaves as not only effector but also modulator of 5-FU when combined with 5-FU and…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE